Psyence Biomedical stock analysis
Psyence Biomedical (PBM) Stock Price & Analysis
PBM Stock Chart & Stats
- Day’s Range
- $2.95 - $3.14
- 52-Week Range
- $1.92 - $18.62
- Previous Close
- $2.94
- Volume
- N/A
- Average Volume (3M)
- 50.86K
- Market Cap
- $11.29M
- Enterprise Value
- -$6.08T
- Total Cash (Recent Filing)
- $733
- Total Debt (Recent Filing)
- $10.45K
- Price to Earnings (P/E)
- ―
- Beta
- 5.11
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Psyence Biomedical News
Psyence Biomedical teams with Benuvia to establish U.S. manufacture of ibogaine
Psyence Biomedical (PBM) announced that its wholly-owned Texas subsidiary, Texas Ibogaine Research Corporation, or TIRC, has entered into a manufacturing services agreement with Benuvia Operations of Round Rock, Texas, establishing
Psyence Biomedical establishes Texas Ibogaine Research Corporation
Psyence Biomedical (PBM) announced the formation of Texas Ibogaine Research Corporation, or TIRC, a Texas-based company established to coordinate the company’s U.S. ibogaine development activities, including pharmaceutical-grade supply, regulatory engagement
PBM FAQ
What was Psyence Biomedical’s price range in the past 12 months?
What is Psyence Biomedical’s market cap?
When is Psyence Biomedical’s upcoming earnings report date?
Is Psyence Biomedical overvalued?
Does Psyence Biomedical pay dividends?
What is Psyence Biomedical’s EPS estimate?
How many shares outstanding does Psyence Biomedical have?
Which hedge fund is a major shareholder of Psyence Biomedical?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Psyence Biomedical
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jody Aufrichtig
- Employees
- 12
- Website
- www.psyencebiomed.com
- Address
- 121 Richmond Street West, Toronto, ON, M5H 2K1, CA
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 3 | 15 |
| Technical Analysis | 4 | 3 | 3 |
| Moving Averages | 0 | 0 | 12 |
